Epetome

Executive Summary

Epetome is a UK-based biotechnology company developing next-generation peptide therapeutics for metabolic and cardiovascular diseases. Founded in 2021 and headquartered in Cambridge, the company leverages a proprietary peptide discovery platform combined with advanced formulation technologies to overcome traditional limitations of peptides, such as poor stability and bioavailability. Its lead programs target key metabolic and cardiovascular pathways, with an initial focus on oral delivery to enhance patient compliance. The company has advanced to Phase 1 clinical development for its lead candidate, demonstrating early proof-of-concept in preclinical studies. With a team of 50-200 employees, Epetome is positioned to address significant unmet needs in chronic disease management. While still private and without disclosed funding rounds, the company's innovative approach to peptide engineering and oral delivery could differentiate it in the competitive biotech landscape. The absence of major catalysts in the immediate term, however, keeps conviction moderate.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Data Readout for Lead Peptide Candidate55% success
• Q2 2026Series A Funding Round70% success
• Q1 2027Strategic Partnership for Oral Delivery Platform40% success